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ABSTRACT
Respiratory Syncytial Virus (RSV) infects the lower respiratory tract in children under the
age of two years and is spread through droplet and contact with infected persons. An
estimated 200,000 children suffer from complications of RSV annually worldwide. Palivizumab
is a monoclonal antibody used to immunize children from RSV and has been on the market
since 1988. In 2014, the American Academy of Pediatrics (AAP) updated its policy for
recommendation of RSV in premature infants. The objective of this capstone is to propose an
evaluation framework with an example of how it could have been applied to assess the impact
of the AAP policy change on RSV vaccination use and RSV outcomes among premature infants.
The proposed evaluation framework would be a unique link between birth certificate
records and surveys of parents/guardians of 32 week gestation premature infants or less in the
metropolitan Atlanta area. The birth certificate data would identify “at risk” infants and would
allow for selection of a sample of parents/guardians, both pre-policy change (August 1, 2013 to
July 30, 2014) and post-policy change (August 1, 2014 to July 30, 2015). The primary endpoints
would be: initiation and completion of the RSV vaccine series and RSV infection rates.
Moderating variables would be obtained from birth certificate data (e.g. mother’s education
and race) and survey data (e.g. attitudes toward vaccine acceptance).
The evaluation framework proposed in this Capstone can be used in future analyses of
RSV vaccination policy changes. It can also be generalized to other geographic areas in the US
and used for routine surveillance of RSV vaccination use and RSV outcomes.
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CHAPTER I: INTRODUCTION
Background
Respiratory Syncytial Virus (RSV) infects the lower respiratory tract in children under the
age of two years and is spread through droplet and contact with infected persons. An estimated
200,000 children suffer from complications of RSV annually worldwide. Once RSV is acquired,
an estimated 25% to 40% of children under the age of one year suffer from severe
complications of the infection (RSV, 2015). It can be prevented with Palivizumab, a monoclonal
antibody used to immunize children from RSV and has been on the market since 1988
(Mahadevia et al., 2012). In 2014, the American Academy of Pediatrics (AAP) updated its
Palivizumab policy guidelines for recommendation of RSV in premature infants.
Some of the symptoms of RSV include cold like symptoms of runny nose, cough, and
fever in healthy children (RSV, 2015). Immuno-compromised children suffer from more severe
complications of lower airways such as bronchiolitis, croup, and pneumonia. The more severe
cases of RSV places babies at risk for hospitalization, oxygen therapy, airway clearance,
intubation and Extra Corporeal Membrane Oxygenation (ECMO), also known as lung bypass
(Regnier et al., 2013).
Due to less developed lung tissue, premature infants are at risk of having severe
complications from RSV. Fetal lung development begins around 22-25 days after conception.
Although there are 5 stages of lung development, the last two stages, saccular from 24-38
weeks gestation and alveolar from 36 weeks gestation up to 3 years of age, places infants at risk
for surfactant deficiency, chronic lung disease, and bronchiolitis (Rubarth and Quinn, 2015).
Table 1 displays the stages of lung development in the growing fetus and infants. Many studies
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show that infections of the lower airway during any of these lung development stages can have
long term effects of asthma, wheezing, and chronic lung disease (Hall et al., 2013).
Table1. Stages of Lung Development in Fetus and Infant
Stage of
Development
Embryonic

Pseudoglandular

Fetal Time
Period
3-7 weeks

Events
Occurring
Respiratory bud
forms, trachea and
larynx forms
Branching
continues, terminal
bronchioles
Development of
bronchioles,
vascularized lung
tissue, gas exchange
at 24 weeks
Terminal sac
increase, surfactant
production
True alveoli
develop

6-16 weeks

Canalicular

16-28 weeks

Saccular

24-38 weeks

Alveolar

36- 3 years

Possible
Defects
TEF,
pulmonary agenesis
CDH, tracheal
atresia, pulmonary
hypoplasia
RDS

RDS

BPD

Helfrich et al. 2015
Abbreviations: TEF, tracheoesophageal fistula; CDH, congenital diaphragmatic hernia; RDS, respiratory distress syndrome;
BPD, bronchopulmonary dysplasia.

Premature infants are more susceptible to severe symptoms of RSV due to their less
developed lung volumes and alveoli, inability to fight off infection, and feeding issues. Infants
born at less than 35 weeks gestation are particularly at higher risk for jaundice, chronic lung
disease, respiratory distress, and longer hospital stay compared to term infants of 37 to 40
week gestation (Helfrich et al., 2015). Nonetheless, many studies have been performed on the
mid and late preterm infants ranging from 30 to 36 weeks gestation concerning effectiveness of
Palivizumab and hospitalization of infants with RSV (Helfrich et al., 2015). Figure 1, shows the
difference in lung volume and alveoli in preterm and a well vascularized term infants lungs.
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Figure 1. Preterm infant Lungs Versus Term Infant Lungs

(Moore and Persaud, 2008; Synagis, 2015)
Objective
The objective of this capstone project is to develop a framework to evaluate the RSV
vaccine initiation, RSV vaccine completion, and acquired RSV infection in premature infants.
Specific aims of this Capstone are:
1)

Propose an evaluation framework that would involve a unique link between
birth certificate records and a survey of parents/guardians with premature
infants identified through the birth certificate records

3

2)

Provide an example of how the evaluation framework could have been used to
assess the impact of a policy change regarding Palivizumab vaccination by the
American Academy of Pediatrics in 2014.

3)

Provide an example of how the evaluation framework can be used for annual
surveillance of RSV vaccination use and RSV outcomes in premature infants
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CHAPTER II: LITERATURE REVIEW
Cost Effectiveness of RSV Vaccination
According to the CDC, in 2014 nearly 58,000 children under the age of five years were
diagnosed, hospitalized, and treated for complications from RSV (RSV, 2015). The cost burden
for RSV infection ranges anywhere from 17,000 to 60,000 dollars per hospitalization per child
(Regnier et al., 2013). Palivizumab immunization was found to be cost effective in early, mid,
and late premature infants who were given the vaccination at or under the age of 6 months
with more than one risk factor (Mahadevia et. al., 2012). Some of the risk factors for low
vaccination status are parental vaccine acceptance, lack of healthcare access, and burden of
monthly injections during the RSV season. The Mahadevia et al. (2012) study examined three
groups of premature infants without lung disease or congenital heart defects. This study found
the RSV vaccination to be cost effective in premature infants with more than one risk factor. It
is strongly recommended by AAP that children with lung disease, congenital Heart disease, and
diseases of airway clearance also receive the vaccination to avoid lengthy hospital stays
(Committee on Infectious Disease, 2014).
A study by S. Riegner (2013) analyzed the healthcare utilization costs for RSV and
Palivizumab vaccine efficacy. This study observed RSV infection and the incidence of asthma
and other sequelae following an RSV infection in children. According to the author, asthma and
wheezing related to RSV decreases as age increases (Riegner, 2013). This study also accounts
for loss from work, transportation to and from hospital, sequelae costs, funeral costs and lost
income from premature death (Regnier, 2013). According to this study, RSV vaccination could
prevent 23,069 hospitalizations and 66 deaths of infants in the USA. Although, less than 3% of
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total RSV infected children require hospitalization from severe symptoms, the majority of
hospitalizations for RSV are 6 months and younger (Kenyunjui et al., 2015). 69% of infants are
infected their first year of life (Regnier et al., 2013.) Nearly all children are infected by two years
of age (RSV, 2015).
Although only 3% of RSV infections require hospitalization, the estimated cost of RSV
burden on United States economy is higher for preterm infants than term infants. The average
cost for a preterm infant is $34,000 per RSV hospitalization versus $9,000 for term infants (Shi
et al., 2011). The cost for a series of 5 Palivizumab injections over an RSV season can range
anywhere from 10,000 to 15,000 (Gutfraind et al., 2015). The study results vary from state to
state, however hospitalization rates of 30 to 50 per 1000 in infants less than 6 months old was
the average. This was the highest number of hospitalizations among each of the groups
studied. The other two groups of infants were 6 to 12 months and greater than 12 months with
hospitalizations at 11 to 15 per 1000 infants and 15 to 26 per 1000 infants respectfully (Hall et
al, 2013). Variability in hospitalization rates among early-preterm, late-preterm, and term
infants are limited by small sample size in this particular study, but many other studies have
explored Intensive Care Unit admissions and severity of symptoms in RSV positive children with
less variability.
A small percentage of children acquire RSV despite vaccination. One retrospective study
by Butt et al. (2009) examined the characteristics of 181 patients admitted to a Pediatric
Intensive Care Unit (PICU) with RSV infection following the implementation of RSV prophylaxis.
Approximately 3% of children who received Palivizumab were diagnosed with RSV. The other
97% of children vaccinated did not acquire RSV. According to this study, four infants were
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preterm (range 27–32 weeks gestational age), whereas two resulted in death; 66.7% had one or
more underlying medical condition, such as congenital heart disease, chronic lung disease, a
neurological disorder or a genetic syndrome (Butt et. al, 2011). 50% of the premature infants
admitted to PICU in this study resulted in death.
A study by Borse et al. (2014) was performed on Alaska Native Infants. Alaska Native
infants have high rates of RSV and are hospitalized more often from complications associated
with RSV. Alaska Native infants have 5 times the rate of hospitalization than the national
average and an RSV season almost twice as long as some states. The cost per vial of Palivizumab
is around $1000 per 0.5 mL vial. The dose is weight dependent at 15mg/kg. The average term
baby weighs around 3.5 kg which would be 0.53mL or an estimated $1000 per child per
injection. Although the premature infant can weigh significantly less than a term infant, the cost
for premature infants to receive anywhere between 5 and 7 injections can be $5000-$7000 per
premature child per RSV season (Synagis, 2016). However, the cost of hospitalization in Alaska
is $3387 per day with an average length of hospital stay for a preterm infant is 7.1 days; an
infant can easily generate a $42000 bill (Borse et al., 2014).

Factors Affecting RSV Rates
There are several factors that increase the risk of acquiring RSV infection. Other than
immunization, the best way to prevent RSV infection is to reduce exposure. RSV is significantly
reduced in infants kept away from daycare, children who are homeschooled, who have no
siblings, good handwashing, and babies born to non-smoker families (Heikkinen et. al., 2015).
Day care attendance can affect whether a child acquires this highly contagious virus by
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increasing contact with other sick children. Unfortunately, many households require both
parents to work and homeschooling or keeping the infants away from outside childcare is not
an option. Also, infants with siblings that attend school or day care could increase exposure to
RSV (Abraha et al., 2015).
The second factor that increases an infant’s risk of acquiring RSV infection is the number
of siblings and family members in the household. Many infants acquire RSV from a sibling or
someone positive in the home during the winter months. Vaccination of family members may
be a productive way of keeping the infant from acquiring this infection (Kanyunjui et al., 2015).
Another study evaluated the number of siblings and sibling ages with infants who were
hospitalized. In children under the age of two years old who were hospitalized with RSV
complications, 76% resided in homes with at least one other sibling (Hall et al., 2013). A
prospective study found that 77% of the RSV cases had family members with positive nasal
swabs (Heikkinen et al., 2015). Nasal swabs are a simple non-invasive way to detect the RSV
viral antigen in the nares and is the main method used by physicians and health care facilities to
diagnose RSV (Kanyunjui at al., 2015: Abraha et al., 2015). Heikkinen et al. (2015) suggest that
immunization of family members could possibly decrease the incidence of premature infants
acquiring RSV.
Children in households with family members who smoke are at greater risk of having
severe complications and hospitalization from RSV than children who are not exposed to
second hand smoke (Heikkinen et al., 2015). Smoking among family members not only
increases respiratory illness in adults, it affects children in the home, but at a much higher rate
than adults (Smoking and Tobacco use, 2015). Children exposed to second hand smoke acquire
8

asthma, bronchitis, and pneumonia more frequently than children who are not exposed due to
the potential decrease of the lower lung development from the chemicals in smoke (Smoking
and Tobacco Use, 2015).
The age at which a premature infant is exposed can affect RSV rates, severity, and
hospitalization. Unfortunately infants under the age of six months appear to have the most
severe cases of RSV infection, while older children and other family members are often carriers
of RSV (Heikkinen et. al., 2015; Abraha et. al., 2015). The results of one other study found that
hospitalization rates of 30 to 50 per 1000 infants for babies less than 6 months old is double
that of infants greater than 12 months old (Hall et al., 2013). The study by Kenyunjui et al.
examined RSV herd immunity and, again, suggested that vaccinating older siblings could help
prevent RSV in babies under the age of 6months. They found that a reduction in hospitalization
could range from 50-70% by vaccinating older children (Kenyunjui et. al., 2015).
Factors Affecting Parents’ Vaccine Acceptance
RSV vaccination and vaccine acceptance rates are difficult to estimate. For one, since it
is not a mandatory vaccination, it does not require reporting to the CDC (Vaccine Coverage,
2015). Secondly, many infants do not receive the total number of recommend Palivizumab
injections during the RSV season. In 2012, Chadha et al. (2012) explored adherence to
recommendations for Palivizumab dosing and found that it is suboptimal in preterm infants
insured by the South Carolina Medicaid program. Only 36%-46% actually received the total
recommended doses. This study did not take into account data from private insurance
companies in the area for comparison. In conclusion, they suggested healthcare professionals
play a vital role in identifying and following up with patients who qualify for Palivizumab dosing
9

in populations with lower SES. Despite the solid evidence of the benefits of Palivizumab in highrisk groups, many who are eligible are not obtaining the vaccination as recommended in the
South Carolina Medicaid Program (Chadha et. al. 2012: Hall et. al., 2012).
There are several factors that affect vaccine acceptance or opposition among parents.
Many parents want to know the risks versus the benefits. A health care provider can provide
literature to determine risks versus benefits. Physician and medical staff play a role as
educators to patients and family members concerning RSV vaccination and prematurity.
Vaccine education may include information on side effects, safety, and efficacy. One study, by
Zimet (2005) explored how parents relied heavily on whether their physician felt the HPV
vaccine safe and necessary. Several registries, such as Vaccine Adverse Event Reporting System
(VAERS), were developed to report adverse reactions from vaccines and medical equipment so
that parents and health care providers could have accurate and update information (VAERS,
2016). Approximately 25% of parents in one study fear that vaccines will lower the child’s
immune system or cause autism or multiple sclerosis (Gaskey et al., 2009).
Following vaccine injection, 10% of patients have a rash or fever up to 3 days (Synagis,
2016). The Canadian Registry of Children Receiving Palivizumab (CARESS) was developed
specifically for reporting adverse reactions to RSV vaccination in Canada. To date, only one case
of anaphylaxis following the Palivizumab injection in an infant has been documented and
published as a case study (Savitz et al., 2014). This study found that out of 13,025 infants that
received the Palivizumab injections, 14 hypersensitivity reactions were reported related as
possibly or probably due to RSV vaccine in six infants. That’s 2.8 per 10,000 or .05% of infants
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having serious complications from RSV vaccinations (Jinghan et al., 2015). This number is,
however, considered safer than the influenza vaccine as reported by the U.S. VAERS. The
influenza vaccine had a risk of febrile seizures reported as 1 per 1,000 children or 0.1% with this
complication in high risk infants (VAERS, 2016).
Several studies have been published on parental vaccine acceptance and Human
Papilloma Virus (HPV) vaccines. The HPV vaccine is similar to RSV in that 1) the patient receives
multiple doses over a six month time period and 2) the vaccines are not mandatory for school
or day care attendance. There could be increased completion of vaccines with a reminder
protocol in place and school-based vaccine programs (Neubrand et al., 2009). A study by
Gerend et al. (2009) observed vaccine attitude responses of parents of daughters who fit the
criteria for HPV vaccine. Greater than 60% had intentions to vaccinate, with 50% actually
receiving the HPV vaccine series (Gerend et al., 2009). Reminders to parents and guardians of
infants and children can improve the rates of vaccine completion (Neubrand et al., 2009).
How physicians respond to patients concerns, patient physician trust, and the number
of patient visits can all affect completion of a vaccine series. Although many parents are not
aware of some of the consequences of some infections, many parents are very interested in
efficacy and physician recommendations. In one article, it was suggested that a goal for
physicians should be to acknowledge and have a positive conversation with parents concerns
about vaccination (Zimet, 2005).
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CHAPTER III: METHODS
Example 1: AAP Policy Change
This example illustrates a hypothetical evaluation of infants of 29 weeks gestation or
less and infants 29-32 weeks gestation for initiation and completion of RSV vaccine series and
for acquired RSV infection pre- and post- policy guideline changes proposed by the American
Academy of Pediatrics (AAP). The AAP policy guideline change is summarized in Table 2.

Table 2. Summary AAP policy guideline changes published August 1, 2014

Gestational age
recommended at less than
one year of age at start of
RSV season
Number of recommended
injections at start of RSV
season
At risk groups

Pre-policy guidelines

Post-policy guidelines

32 week gestation

Less than 29 week gestation

6 injections

5 injections

Premature, heart disease(may
have up to 2 years of age),
Chronic Lung disease, airway
clearance diseases

Premature, heart disease,
Chronic Lung disease, airway
clearance diseases

Study Design
The American Academy of Pediatrics (AAP) is an organization that dedicates its work to
infants and children through evidence-based practice. In 1988, the AAP developed a policy
guideline for practitioners on the administration of Palivizumab following the Food and Drug
Administration (FDA) approval and has been revised and updated in 2009, 2012, and 2014
(Committee on Infectious Disease, 2014). The original policy guideline of 1988 recommended
the population at risk of severe complications which includes infants one year or less at the
12

start of RSV season who are less than 35 weeks gestation, infants with chronic lung disease,
congenital heart defects, and disorders that decrease lung clearance, such as cystic fibrosis
receive Palivizumab (Committee on Infectious Disease, 1988). In the policy update of RSV
guidance for Palivizumab prophylaxis, developed and printed in 2014, the gestational age at
which a premature infant was recommended to receive the vaccine was changed from less than
32 weeks gestation to less than 29 weeks gestation. Premature infants between the ages of 29
and 32 weeks gestation are no longer recommended to receive the vaccine.
This capstone project proposes a framework to evaluate responses to RSV vaccine
recommendations for premature infants in the AAP policy guideline update. Birth certificate
data will be used to define the study sample from 28 counties in the metropolitan Atlanta area
(28 County MSA Map, 2016). A parent RSV survey questionnaire will be used to assess RSV
vaccination initiation and completion in less than 29 week gestational age infants and for
infants of gestational ages 29-32 weeks, acquired infection in pre- and post- policy guideline
changes.

Study Period
The policy guideline update was published August 1, of 2014. This project defines the
pre-policy time period from August 1, 2013 to July 30, 2014. The post-policy time period will be
defined as August 1, 2014 to July 30, 2015. This gives a total of two years, one year before and
one year after the policy to evaluate the change.
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Study Data
Birth Certificate Records
This project proposal uses birth certificate information to obtain a sample of premature
infants from 28 counties in the metropolitan Atlanta area. I will obtain birth certificates from
the Georgia Department of Vital Statistics (GDVS) for the time period of August 1, 2013 to July
30, 2015, based on a year prior to and a year after policy change on August 1, 2014 (Georgia
Department of Public Health, Vital Records, 2016). The GDVS will require a request and
acceptance of terms and conditions prior to use of private birth certificate information. The
Georgia Birth Certificate in Appendix A has mother/guardian address and phone number at
time of birth, gestational age, and county of birth. Gestational age will be used to determine
those infants less than one year at the start of RSV season. The mothers/ guardian’s address
and phone number will be used as contact information for delivery of survey packets and
postcard reminders. The Georgia Birth Certificate also includes type of insurance, prenatal care,
occupation, age, education level, and race.

Multi-modal Survey
A written parent RSV survey tool will be developed and administered to a sample of
mothers with infants of 32 weeks gestational age or less during the study period. With the
decline of home phone landlines, written mail-back surveys are still one of the most reliable
methods of administering survey with good response rates at approximately 50-70% (Rookey et
al., 2012). A draft of the parent/guardian RSV survey instrument is included in Appendix B.
With the use of Optical Character Recognition (OCR), data entry can be made simple. It converts
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images typed, handwritten or printed into machine encoded text via scanner (Biondich et al.,
2002).
Some of the proposed survey items were based on routine influenza
immunization survey questions from the National Immunization Survey (Vaccine Coverage NIS,
2016). NIS includes information on attitudes toward immunization from influenza, Human
Papilloma Virus (HPV) vaccinations, routine child immunizations and other information related
to mandatory children vaccinations of Diphtheria, Pertussis, Tetanus (DPT) and Measles,
Mumps, Rubella (MMR). An analogy between influenza vaccine and RSV vaccine was derived
since there was little data to support RSV factors alone ( Trivalent Influenza Vaccine Data,
2016).

Sample Size Estimate
I will administer the survey to a sample of mothers with infants of 32 week gestational
age or less in the pre- and post-policy guideline change period. The target sample of completed
surveys is 100 Caucasian and 100 African American mothers in the pre-policy sample period and
100 Caucasian and 100 African Americans in the post-policy sample period.
The total number of premature births in the metropolitan Atlanta should be sufficient to
achieve an adequate sample size assuming there is a 50% response rate to the survey. In
Georgia there were 128,748 births in 2014 (Vital Records, 2016: OASIS, 2016). Of these,
approximately 59,731 (46.4%) were born to Black or white women in the metropolitan Atlanta
area. Of these 34,021 were Caucasian mothers and 25,710 to African American mothers
(OASIS, 2016). African American women have a higher premature birth rate than Caucasian
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women. From national statistics, approximately 1.5% of births are between 29 and 32 weeks
gestational age, giving us 510 Caucasian women and 386 African American women to sample
(NVSS, 2014). Infants under 29 weeks gestation are roughly 0.92% of total births. However,
survival rates are proportional to the gestational age. An infant born at 28 weeks gestational
age has a higher chance of survival than a 25 week gestational age premature infant. My initial
sample could be as high as 255 Caucasian and 118 African American responses from the survey
during the post-policy guideline change. While this is not an exact range for RSV risk, I expect
the approximate sample on this order of magnitude. For the pre-policy sample size estimate, I
will use 2013 birth data.

Survey Administration
The survey will randomly sample Caucasian (N=100) and African American (N=100)
mothers of premature infants of 29-32 gestational ages in the pre- and post-policy periods. A
minimum of 50-60 completed surveys will be from Caucasian and African American women
each in the pre- and post- policy period is desired. The approach will be used for infants less
than 29 weeks gestational age.
The survey will be administered following the RSV season in Georgia using a mixedmode (written mail-in form and online survey form) after March 30th. The initial mailing for
each RSV season will be delivered to the address of the mother on the birth certificate
beginning April 20. For the babies identified as pre-policy (between August 1, 2013 and
February 28, 2014) candidates, mailings would be delivered April 20, 2014, had the framework
been in effect prior to the AAP policy change. March marks the end of the season and eligible
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infants will receive the vaccine at the next RSV season. Mothers of infants born March 1, 2014
through February 28, 2015 will receive a survey packet starting April 20, 2015. Mothers of
infants born March 1, 2015 through July 30, 2015 would receive survey packets after the 20152016 RSV season beginning April 20, 2016. The timing of survey administration is designed to
reduce recall bias by delivering the surveys to mothers as close to the RSV season as possible.
Packets will be delivered staggered every three weeks until all surveys have been
disbursed. The mailing will include a cover letter with the website link to the online
questionnaire, instructions, the survey instrument and a prepaid return envelope.
Undeliverable returns will be investigated and an attempt to identify the current location of the
mother via phone number. For unreturned surveys, a postcard reminder will be mailed after 2
weeks. The mothers that are contacted by phone will be mailed a new packet to the corrected
address. A third mailing will be the entire packet to those addresses of unreturned surveys.
The online survey format will be parallel to the written survey format. The online survey tool
will have questions worded for online administration with a bubble answer method from
reputable and confidential survey software company (Dillman et al. 2012). Data from the
written survey will be entered by a trained research assistant into an Excel database. For the
online portion, the birth certificate number will be the survey ID and the participant can create
a login password. The online data will be linked to birth certificate through the birth certificate
number.
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Human Subjects
Birth certificates are not public records. The GDVS provides access to birth certificate
record information for research purposes through a request process. I will gain access by
requesting permission from the GDVS and following the application process and guidelines. I
will also obtain IRB approval through the Office for Human Research Protections for Human and
Children Subjects as necessary. IRB approval can either be obtained via online application or
paper submission (IRB, 2015). Georgia State University has a process for registering and
applying online through a program called iRIS. Appendix C shows IRB questions and potential
responses. Most institutions require legal and compliance review to satisfy human subject
related research.

Example 2: Ongoing Surveillance of the RSV Season
In addition to providing (a hypothetical) assessment of how the AAP policy change might
have affected RSV vaccination initiation and completion and RSV infection rates, the linked
survey and birth certificate records could provide a framework for routine monitoring annually
following the RSV season.
This proposed surveillance could complement current RSV surveillance. Current RSV
surveillance monitoring is available from The National Respiratory and Enteric Virus Survey
System (NREVSS) which shows RSV trends through positive RSV Antigen Detection Tests.
Results are sent by state laboratories to NREVSS. These data are limited to state and national
onset, peak, and ending of RSV season. These data can provide a context for comparison to the
proposed survey timed measures of RSV infection rates in a particular state. Figure 2 shows a

18

NREVSS graph of total RSV Antigen Detection Tests with the percent positive test results. The
RSV season is defined as a sharp slope in positive RSV antigen tests. In the state of Georgia, the
RSV season is defined in the chart from October 1, to March 30 (NREVSS, 2015).
Figure 2. NREVSS data for Georgia

(NREVSS, CDC, 2016)

Study Measures
The study measures consist of primary endpoints which are noted in Table 3 as
dependent variables. Table 3 also lists independent and other potential variables of interest
that were gathered from the Georgia Birth Certificate and the parent RSV Survey. The
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endpoints can be measured from survey data and analyzed with some of the various
independent variables gathered from both the survey and the birth certificate.
Table 3. Variables for RSV Surveillance
Dependent Variables
Independent survey Variables
Vaccine initiated
Race
Vaccine completed
Household size/siblings
Acquired RSV
Use of Childcare
Vaccine acceptance

Potential Independent Variables
Maternal Age
Literacy
Marital Status
Insurance Status

Table 2 lists the independent, dependent, and potential variables found on the survey questionnaire and the birth certificates.

Dependent Variables
The primary endpoints will be obtained from survey data. The three primary endpoints
will be defined as:
Initiation: The premature infant received at least 1 RSV injection for the RSV season
Completion: The premature infant received at least 5 RSV injections for the RSV season
Infection: The premature infant had a positive RSV Antigen Detection Test or was told by
a healthcare provider that the infant has RSV.

Independent Variables
The independent variables are: 1) mother’s race, 2) household size, 3) use of childcare,
4) vaccine acceptance, 5) maternal age, 6) literacy, 7) Insurance status, and 8) marital status.
Mother’s race, age, marital status and insurance status are available from birth certificate
records. Parental vaccine acceptance, household size and number of siblings, daycare
attendance, literacy, and the primary endpoints are items on the RSV survey.
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Insurance Status
Insurance status is a Georgia Birth certificate item. Insurance status will be classified as
private, Medicaid, or uninsured. Studies indicate lower levels of health care and preventive
services use in Medicaid plans. For example, Hall et al. (2013) as well as DeJongh et al. (2012)
have compared private and Medicaid insurance on hospitalization and cost effectiveness in
premature infants. Also, research performed in states with special circumstances, such as
Alaska, use Medicaid data alone since all premature infants are Medicaid eligible (Borse et al.,
2014).

Vaccine Acceptance
Vaccination acceptance is another unique variable of interest on the survey
questionnaire. Parental attitudes vary from mandatory to non-mandatory vaccines. Mandatory
vaccines such as Measles, Mumps, Rubella (MMR), Influenza, or Diphtheria, Pertussis, Tetanus
(DPT) have nearly 100% vaccination rates in the state of Georgia (Trivalent Influenza Vaccine
data,2016 :NIS, 2015). RSV immunizations average 35-45% completion with many Primary Care
Providers in some studies.

Maternal Age
Maternal age is located on birth certificate data and will be categorized into three
groups. The largest group of mothers delivers infants between 20 and 34 years of age. Mothers
under the age of 20 years are considered a teenage mother. Mothers greater than or equal to
35 years of age are considered advanced maternal age (Data and Statistics, 2016). Young

21

maternal age as well as advanced maternal age have been well studied for pregnancy outcomes
and are at higher risk of having premature infants (Locke et al., 2012).

Number of Siblings
Siblings and other adults in the household can be carriers. An infant’s risk of acquiring
RSV increases with the number of siblings in the household that attend public or private
daycares or schools (Kanyunjui et al., 2015). Palivizumab is not mandatory for daycare or school
as with some other vaccines. The larger the household, the more potential exposure and risk of
RSV for premature infants exist. Household size and number of siblings are question items on
the survey.

Public Daycare
The use of public daycare can increase the risk of acquiring RSV in premature infants.
Many infants can become exposed to RSV and many other viruses in environments with other
infants and children (Abraha et al., 2015). A child is most contagious at 3-4 days once infected
with RSV and begins displaying cold like symptoms. The child could remain contagious for a
week or even longer in immune compromised children (RSV, 2015). It only takes one sick child
to infect every other child in close proximity.

22

Mother’s Education
Mother’s education is available on birth certificate records and will be classified as: high
school education (or GED) or less, some college or trade school, bachelor’s degree from college
or trade school, or post-graduate degree.

Mother’s Literacy
The Single Item Literacy Screen (SILS) is a single question that is used to determine adult
literacy and will be one of the survey items. This question determines how difficult it is to read
printed health material and is rated 1-5 with 1= never and 5=always. The SILS question reads:
“How often do you need to have someone help you when you read instructions, pamphlets, or
other written material from your doctor or pharmacy?” (Morris et al., 2006). Most printed
health material is on a marginal reading level of sixth-eighth (Badarudeen and Sabharwal,
2010). The SILS distinguishes functional reading level of less than 5th grade to marginal reading
level. Based on this SILS, a score greater than two may indicate some level of difficulty with
reading printed health related material used on the survey (Morris et al., 2006).
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CHAPTER IV: STATISTICAL METHODS
Example 1: AAP Policy Change
Analysis of the AAP policy change will compare RSV vaccination initiation and
completion and RSV infection rates between the pre- and post-policy RSV seasons (Appendix
D). Two subsets of premature infants will be compared: those under29 weeks of age, and those
29-32 weeks of age. This is important because post-policy the 29-32 week group was not
recommended for RSV vaccination and a decrease in RSV vaccination rates might be associated
with an increase in RSV infections.
Relationships between each of the endpoints and pre- and post-policy change periods
will be evaluated by chi-squared statistics. I will use SAS 9.4 (SAS institute, Cary, NC) to test for
significance using the conventional p-value of ≤0.05. An example of the hypothesis to be tested
is:
Null Hypothesis:
•

No difference in RSV vaccine initiation among infants less than 29 weeks
gestational age between the pre- and post-policy periods.

Alternative Hypothesis:
•

Premature infants less than of 29 weeks gestational age will have a
higher rate of RSV vaccine initiation in the post-policy period compared
to the pre-policy period.
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Example 2: On-going Surveillance of the RSV Season
Ongoing surveillance would follow the same general approach as described for Example
1. For example, the association of insurance status with each of the 3 endpoints could be
annually evaluated among premature infants less than 29 weeks gestation:
Null hypothesis 1:


There is no difference in RSV vaccination completion by insurance status.

Alternative hypothesis 1:


There is a significant difference in RSV vaccination completion if the
infant has private insurance or Medicaid.

Other examples with relevance for health policy or medical practice management are
presented in Appendix E.
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CHAPTER V: DISCUSSION
This capstone proposes a unique framework by using birth certificate records and a
Parent RSV survey tool to evaluate RSV outcomes in premature infants. In my first example, I
used the Palivizumab Update in policy guidelines by the AAP. No identifiable national
databases such as NHANES could have been used to evaluate this policy guideline change in
2014 so I developed the proposed evaluation framework. Consequently, the impact of the AAP
policy change remains unknown. It may be possible, however, to assemble other data to assess
the impact. But, if my proposed evaluation framework (or something similar) had been in
routine use in one or more locations in the US, then evaluation of the AAP policy change impact
would have been possible.
The second example illustrates how my proposed evaluation framework can be used for
ongoing surveillance framework of RSV vaccination status, RSV infection rates, and other
factors that might affect these outcomes among premature infants. The linking of birth
certificate records with survey results from a sample of parents/guardians of premature infants
makes my capstone proposal innovative. Most other studies on RSV have used hospital and
clinic data for routine surveillance. My proposed evaluation framework can be generalized for
routine annual surveillance and to other locations in the US.

Limitations
One of the challenges with my proposed evaluation framework capstone is the number
of premature infants could be potentially small due to low premature survival rates after birth.
Many infants may not live to go home, particularly under 29 week gestational age. Most other
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studies have very small numbers (less than 2.5% of infants born are less than 32 weeks
gestational age) that show inconsistency and variability in outcomes due to sample size. Using
this framework on an annual basis would allow the sample size to be increased through each
additional year. This would allow for more reliable assessments of the associations such as
maternal literacy or use of child daycare with RSV vaccine initiation and completion and RSV
infection rates. There is also the potential for recall bias or for social desirability bias from
mothers of premature infants who respond to the survey.
Summary
The RSV vaccine has been demonstrated to be safe and effective in preventing RSV
infections among infants of 32 weeks gestational age and younger. I proposed an evaluation
framework that uses birth certificate records to identify mothers of these premature infants,
samples those mothers for survey, and links the survey responses to the birth certificate
records. This framework could have been use to evaluate the AAP policy change on which “at
risk” premature infants should have been vaccinated. One outcome of particular interest is the
29 to 32 week gestational age infant that might have been potentially affected by this policy
change. This group of premature infants is no longer recommended to receive the Palivizumab
vaccination. I also described how this approach of using birth certificate and survey data might
be used for routine surveillance of RSV vaccine initiation and completion and RSV infection.
Data collected from the birth certificate records and parent/guardian survey could also be
helpful in understanding factors that affect RSV vaccine uptake and RSV infection rates.

27

REFERENCES

Abraha, H. Y., Lanctôt, K. L., & Paes, B. (2015). Risk of respiratory syncytial virus infection in preterm
infants: reviewing the need for prevention. Expert Review of Respiratory Medicine, 1–21.
http://doi.org/10.1586/17476348.2015.1098536
Analytics, Business Intelligence and Data Management | SAS. (n.d.). Retrieved May 4, 2016, from
http://www.sas.com/en_us/home.html
Atlanta (city) QuickFacts from the US Census Bureau. (n.d.). Retrieved February 23, 2016, from
http://quickfacts.census.gov/qfd/states/13/1304000.html
Badarudeen, S., & Sabharwal, S. (2010). Assessing Readability of Patient Education Materials:
Current Role in Orthopaedics. Clinical Orthopaedics and Related Research®, 468(10), 2572–
2580. http://doi.org/10.1007/s11999-010-1380-y
Biondich, P. G., Overhage, J. M., Dexter, P. R., Downs, S. M., Lemmon, L., & McDonald, C. J. (2002). A
modern optical character recognition system in a real world clinical setting: some accuracy and
feasibility observations. Proceedings / AMIA ... Annual Symposium. AMIA Symposium, 56–60.
Borse, R. H., Singleton, R. J., Bruden, D. T., Fry, A. M., Hennessy, T. W., & Meltzer, M. I. (2014). The
Economics of Strategies to Reduce Respiratory Syncytial Virus Hospitalizations in Alaska. Journal
of the Pediatric Infectious Diseases Society, 3(3), 201–212. http://doi.org/10.1093/jpids/pit072
Butt, M. L., Symington, A., Janes, M., Elliott, L., Steele, S., & Paes, B. A. (2011). The impact of
prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective,
single-centre study. European Journal of Pediatrics, 170(7), 907–913.
http://doi.org/10.1007/s00431-010-1376-3

28

Carbonell-Estrany, X., Pérez-Yarza, E. G., García, L. S., Guzmán Cabañas, J. M., Bòria, E. V., Atienza, B.
B., & IRIS (Infección Respiratoria Infantil por Virus Respiratorio Sincitial) Study Group. (2015).
Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in
Preterm Infants—The SPRING Study. PLOS ONE, 10(5), e0125422.
http://doi.org/10.1371/journal.pone.0125422
Caskey, R., Lindau, S. T., & Alexander, G. C. (2009). Knowledge and Early Adoption of the HPV
Vaccine Among Girls and Young Women: Results of a National Survey. Journal of Adolescent
Health, 45(5), 453–462. http://doi.org/10.1016/j.jadohealth.2009.04.021
Chadha, A. D., Bao, W., Holloway, J., Mann, J., Rye, A. K., & Brown, D. E. (2012). Respiratory Syncytial
Virus Morbidity and Outpatient Palivizumab Dosing in South Carolina, 2004–2009: Southern
Medical Journal, 105(8), 399–404. http://doi.org/10.1097/SMJ.0b013e31825ea57d
Chen, J. J., Chan, P., Paes, B., Mitchell, I., Li, A., Lanctôt, K. L., & CARESS investigators. (2015). Serious
Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for
Respiratory Syncytial Virus Prevention. PLOS ONE, 10(8), e0134711.
http://doi.org/10.1371/journal.pone.0134711
Committee on Infectious Diseases. (2009). Modified Recommendations for Use of Palivizumab for
Prevention of Respiratory Syncytial Virus Infections. PEDIATRICS, 124(6), 1694–1701.
http://doi.org/10.1542/peds.2009-2345
28 COUNTY MSA Map and Text.indd - metro-atl_28-county-map-and-list_3_6_12.pdf. (n.d.).
Retrieved February 23, 2016, from http://www.metroatlantachamber.com/docs/researchdocuments-/metro-atl_28-county-map-and-list_3_6_12.pdf?sfvrsn=2

29

Data and Statistics | Reproductive Health | CDC. (n.d.). Retrieved May 4, 2016, from
http://www.cdc.gov/reproductivehealth/data_stats/
De Jongh, B. E., Locke, R., Paul, D. A., & Hoffman, M. (2012). The differential effects of maternal age,
race/ethnicity and insurance on neonatal intensive care unit admission rates. BMC Pregnancy
and Childbirth, 12(1), 97. http://doi.org/10.1186/1471-2393-12-97
Dillman, D. A. (2006). Why Choice of survey Mode Makes a Difference. Public Health Reports,
121(1)(Jan-Feb), 11–13.
Friedman, D. M., Domachowske, J. B., Wong, P. C., Parimi, P. S., Garcia, D. F., Marcus, M. G., …
Kumar, V. R. (2015). Perceived Risk of Severe Respiratory Syncytial Virus Disease and
Immunoprophylaxis Use Among US Pediatric Specialists. Clinical Pediatrics.
http://doi.org/10.1177/0009922815604598
Georgia Department of Public Health, Office of Health Indicators for Planning OASIS. (n.d.). Retrieved
February 23, 2016, from https://oasis.state.ga.us/oasis/oasis/qryMCH.aspx
Gerend, M. A., Weibley, E., & Bland, H. (2009). Parental Response to Human Papillomavirus Vaccine
Availability: Uptake and Intentions. Journal of Adolescent Health, 45(5), 528–531.
http://doi.org/10.1016/j.jadohealth.2009.02.006
Goodman, M. S., Griffey, R. T., Carpenter, C. R., Blanchard, M., & Kaphingst, K. A. (2015). Do
Subjective Measures Improve the Ability to Identify Limited Health Literacy in a Clinical Setting?
The Journal of the American Board of Family Medicine, 28(5), 584–594.
http://doi.org/10.3122/jabfm.2015.05.150037

30

Gutfraind A, Galvani AP, & Meyers L. (2015). EFficacy and optimization of palivizumab injection
regimens against respiratory syncytial virus infection. JAMA Pediatrics, 169(4), 341–348.
http://doi.org/10.1001/jamapediatrics.2014.3804
Hall, C. B., Weinberg, G. A., Blumkin, A. K., Edwards, K. M., Staat, M. A., Schultz, A. F., … Iwane, M. K.
(2013). Respiratory Syncytial Virus-Associated Hospitalizations Among Children Less Than 24
Months of Age. PEDIATRICS, 132(2), e341–e348. http://doi.org/10.1542/peds.2013-0303
Health, C. O. on S. and. (2015, December 2). Smoking and Tobacco Use; Fact Sheet; Health Effects of
Secondhand Smoke. Retrieved December 2, 2015, from
http://www.cdc.gov/tobacco/data_statistics/fact_sheets/secondhand_smoke/health_effects/
Heikkinen, T., Valkonen, H., Waris, M., & Ruuskanen, O. (2015). Transmission of Respiratory Syncytial
Virus Infection Within Families. Open Forum Infectious Diseases, 2(1), ofu118–ofu118.
http://doi.org/10.1093/ofid/ofu118
Helfrich, A. M., Nylund, C. M., Eberly, M. D., Eide, M. B., & Stagliano, D. R. (2015). Healthy Latepreterm infants born 33–36+6 weeks gestational age have higher risk for respiratory syncytial
virus hospitalization. Early Human Development, 91(9), 541–546.
http://doi.org/10.1016/j.earlhumdev.2015.06.009
IRB Registration Form. (2015, December 2). Retrieved December 2, 2015, from
http://www.hhs.gov/ohrp/assurances/forms/irb_registration_form_.html
Kinyanjui, T. M., House, T. A., Kiti, M. C., Cane, P. A., Nokes, D. J., & Medley, G. F. (2015). Vaccine
Induced Herd Immunity for Control of Respiratory Syncytial Virus Disease in a Low-Income
Country Setting. PLOS ONE, 10(9), e0138018. http://doi.org/10.1371/journal.pone.0138018

31

La Gamma, E., Kumar, V., Wadhawan, R., Ye, S., Sifakis, F., Ycas, J., & Ambrose, C. (2015). Receipt of
Palivizumab before Birth Hospitalization Discharge among Preterm Infants in the United States.
American Journal of Perinatology, 32(11), 1017–1023. http://doi.org/10.1055/s-0034-1543951
Mahadevia, P. J., Masaquel, A. S., Polak, M. J., & Weiner, L. B. (2012). Cost utility of palivizumab
prophylaxis among pre-term infants in the United States: a national policy perspective. Journal
of Medical Economics, 15(5), 987–996. http://doi.org/10.3111/13696998.2012.690013
Vaccination Coverage | NIS Child | Data for 2014 | CDC. (n.d.). Retrieved February 23, 2016, from
http://www.cdc.gov/vaccines/imz-managers/coverage/nis/child/data/tables-2014.html
Morris, N. S., MacLean, C. D., Chew, L. D., & Littenberg, B. (2006). The Single Item Literacy Screener:
Evaluation of a brief instrument to identify limited reading ability. BMC Family Practice, 7(1),
21. http://doi.org/10.1186/1471-2296-7-21
2011-2012 National Survey of Children’s Health Frequencies - create_formatted_frequencies.pdf.
(2015, December 9). Retrieved December 9, 2015, from
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/slaits/nsch_2011_2012/04_List_of_variables_and
_frequency_counts/create_formatted_frequencies.pdf
2013-2014 National Survey of Children’s Health Frequencies - create_formatted_frequencies.pdf.
(2015, December 9). Retrieved December 9, 2015, from
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/slaits/nsch_2013_2014/04_List_of_variables_and
_frequency_counts/create_formatted_frequencies.pdf
Neubrand, T. P. L., Breitkopf, C. R., Rupp, R., Breitkopf, D., & Rosenthal, S. L. (2009). Factors
Associated With Completion of the Human Papillomavirus Vaccine Series. Clinical Pediatrics,
48(9), 966–969. http://doi.org/10.1177/0009922809337534

32

NREVSS | RSV National Trends | CDC. (2015, November 12). Retrieved November 12, 2015, from
http://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html
Pike, K. C., & Lucas, J. S. A. (2015). Respiratory consequences of late preterm birth. Paediatric
Respiratory Reviews, 16(3), 182–188. http://doi.org/10.1016/j.prrv.2014.12.001
Premature Birth. (2015, November 12). Retrieved November 12, 2015, from
http://www.cdc.gov/features/prematurebirth/
Régnier, S. A. (2013). Respiratory syncytial virus immunization program for the United States: Impact
of performance determinants of a theoretical vaccine. Vaccine, 31(40), 4347–4354.
http://doi.org/10.1016/j.vaccine.2013.07.024
Rookey, B. D., Le, L., Littlejohn, M., & Dillman, D. A. (2012). Understanding the resilience of mail-back
survey methods: An analysis of 20years of change in response rates to national park surveys.
Social Science Research, 41(6), 1404–1414. http://doi.org/10.1016/j.ssresearch.2012.06.004
Rubarth, L. B., & Quinn, J. (2015). Respiratory Development and Respiratory Distress Syndrome.
Neonatal Network, 34(4), 231–238. http://doi.org/10.1891/0730-0832.34.4.231
RSV | About the Virus | Respiratory Syncytial Virus | CDC. (n.d.). Retrieved May 4, 2016, from
http://www.cdc.gov/rsv/about/index.html
Savitz, J., Geaney, C., & Banks, T. A. (2014). A case of anaphylaxis to palivizumab. Annals of Allergy,
Asthma & Immunology, 113(2), 236–237. http://doi.org/10.1016/j.anai.2014.06.006
Shi, N., Palmer, L., Chu, B.-C., Katkin, J. P., Hall, C. B., Masaquel, A. S., & Mahadevia, P. J. (2011).
Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a
Medicaid claims analysis in early-preterm, late-preterm, and full-term infants. Journal of
Medical Economics, 14(3), 335–340. http://doi.org/10.3111/13696998.2011.578188

33

Synagis dosing calculator https://www.synagis.com/hcp/aboutsynagis/dosing.html?source=SYNH35744&WT.mc_id=SYNH35744&ut Synagys Palivimub, Mrach
15, 2016
Vaccine Adverse Event Reporting System. (n.d.). Retrieved May 4, 2016, from
https://vaers.hhs.gov/index
Vaccination Coverage | NIS Child | Data for 2014 | CDC. (n.d.). Retrieved February 23, 2016, from
http://www.cdc.gov/vaccines/imz-managers/coverage/nis/child/data/tables-2014.html
Vital Records | Georgia Department of Public Health. (n.d.). Retrieved May 4, 2016, from
https://dph.georgia.gov/VitalRecords
Weiner, L. B., Masaquel, A. S., Polak, M. J., & Mahadevia, P. J. (2012). Cost-effectiveness analysis of
palivizumab among pre-term infant populations covered by Medicaid in the United States.
Journal of Medical Economics, 15(5), 997–1018. http://doi.org/10.3111/13696998.2012.672942
Zimet, G. D. (2005). Improving adolescent health: Focus on HPV vaccine acceptance. Journal of
Adolescent Health, 37(6), S17–S23. http://doi.org/10.1016/j.jadohealth.2005.09.010

34

APPENDIX A
State of Georgia birth Certificate example
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APPENDIX B
Parent/Guardian RSV Survey Instrument

Survey Questions
How often do you need to have
someone help you when you read
instructions, pamphlets, or other written
material from your doctor or pharmacy?

1=never
2=almost never
3=sometimes
4=often
5=always
YN

Did your premature infant have or ever
had chronic lung disease, heart disease, or
disease affecting airway clearance?
1. Do you have a premature infant
between 29 and 32 week gestation?
2. Have your premature infant ever
been diagnosed with RSV in the 1st year of
life?

YN

3. Did your premature infant have to be
hospitalized for RSV?
4. Did your child receive RSV
vaccination at less than 1 year of life?

YN
YN

5.Family Household:
5a.How many people are in your
household?
5b.How many working adults are in
your household?
5c.Do you or the premature child
receive Medicaid and/or private insurance?
5d.Family income?
a. <20,000
b. 20K-49K
c. 50K-79K
d. 80K-119K
e. >120K

1 2 3 4 5+
1 2 3 4 5+
YN

6.Day care situation:
6a.Do any of the siblings attend
daycare or school?
6b.Does the premature infant
attends or has ever attended daycare at
less than 1 year of life?
6c.How often does he or she attend
daycare?

YN
YN
YN
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7.RSV immunization:
7a.Would you or have you initiated
vaccination for your premature infant for
RSV?
7b.If you have initiated vaccination,
did your premature infant receive first
dose in hospital?
7c.How many doses did your baby
receive?
7d.Did you receive the total
recommended RSV doses for your
premature infant?
7e.If you do not plan on vaccinating,
why not?
i.Due to religious belief?
ii.Due to potential harm to child?
iii.Due to lack of exposure to
disease?( circle one or more)no day
care, no siblings in school or daycare,
No one in home smokes.
iv. Due to ( circle one or more)
lack of access to health care provider,
Transportation, unable to get
adequate appointment time.

YN
YN
YN
YN
YN
YN
YN

12345
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APPENDIX C
IRB Human Subjects Form
1. The purpose of the project and project background. To describe the research question
and literature review.
In August of 2014, The American Academy of pediatrics updated the RSV policy
guidelines for Palivizumab for premature infants. The objective of this project is to
develop a framework to evaluate the health effects of the AAP policy change concerning
premature infants 29-32 week gestational age. This project will also address some of the
factors affecting immunization rates particularly the attitudes of parents concerning
health benefits and harm of RSV immunization in Georgia and differences in the
metropolitan Atlanta area.
2.

Recruitment procedures and participant population. This section profiles the
participants, exclusion criteria, how we will recruit and sensitive subjects, incentive
information.
A sample of 400 women 0f 29-32 gestational age infants will be randomly selected from
birth certificate information in the 28 metro Atlanta counties in the pre- and post- policy change
periods. The survey goal is to obtain 200 completed surveys from both Caucasian and African
American mothers /guardians of premature infants in the pre- and post-policy periods.

3. Informed consent process.
We will mail a packet with survey, informed consent form and information. If
the packet is not returned completed or undeliverable, we will contact the mother by
phone.
4. Procedures and Methodology/ research protocol. A step-by step explanation of research
activities.
(methods section)
5. Participants debriefing and feedback.
The participant will be given a feedback form for suggestions.
6. Potential risks to dignity, rights, health welfare of participants.
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Potential risks to dignity will be minimal as this will be anonymous. The
participant has the right to withdraw from the survey study at any time. This project has
no health risk to the infant and mother.
7. Confidentiality and safeguards to minimize risk.
The sample will be obtained randomly and information organized by birth
certificate number.
8. Study benefits.
The benefits of the study will provide insight into vaccination tendency and
infant risk of 29-32 week gestational age infants. Also to assess if there is difference in
initiation, completion and acquired infection in infants less than 29 weeks gestation preand post-policy change is a goal.
9. Researcher’s qualifications and experiences.
The author is master’s public health student under the supervision of thesis
committee consisting of instructors with PHD and MD degrees.
10. Checklist: Human subjects, the use of surveys, consent forms.
To obtain a CITI certified research assistant, I will advertise through Public Health
Program Schools. After obtaining phone numbers and address, we would send questionnaires
to premature infant’s mother concerning RSV vaccinations, attitudes of likelihood to vaccinate,
family and siblings info. A follow-up phone call if survey was not received and mail another
survey are some alternatives to boost low responses.
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APPENDIX D
2x2 Tables for example 1 AAP change:
RSV vaccine initiation in infants less than 29 weeks gestational age, completion, and acquired
infection RSV

1)
Vaccine initiation
Pre-policy

Y
a

N
b

Post-policy

c

d

2)
Vaccine completion
Pre-policy

Y
a

N
b

Post-policy

c

d

3)
Acquired RSV infection
Pre-policy

Y
a

N
b

Post-policy

c

d
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APPENDIX E
Example 2 Ongoing RSV Surveillance
Insurance status with RSV vaccine initiation, completion, and acquired RSV infection

1)

Initiated vaccine

Insurance status

Y

N

Medicaid

a

b

Private

c

d

Uninsured

e

f

2)

Completed vaccine

Insurance status

Y

N

Medicaid

a

b

Private

c

d

Uninsured

e

f

3)

Acquired RSV infection

Insurance status

Y

N

Medicaid

a

b

Private

c

d

Uninsured

e

f
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